[go: up one dir, main page]
More Web Proxy on the site http://driver.im/
Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • NEWS

Heralded Alzheimer’s drug works — but safety concerns loom

Eisai and Biogen share clinical trial data confirming that lecanemab slows mental decline, amid reports of potentially related deaths.
  1. McKenzie Prillaman
    View author publications

    You can also search for this author in PubMed  Google Scholar

Access through your institution
Buy or subscribe

Researchers have got a first look at phase III clinical trial data for a much-lauded experimental Alzheimer’s drug — and although the data suggest that it has a moderate cognitive benefit for people, scientists worry about its safety.

Access options

Access through your institution

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Nature 612, 197-198 (2022)

doi: https://doi.org/10.1038/d41586-022-04240-z

References

  1. Van Dyck, C. H. et al. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2212948 (2022).

    Article  Google Scholar 

Download references

Subjects

Latest on:

Nature Careers

Jobs

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing

Search

Advanced search

Quick links